

Therapy	Mechanism of Action	Sponsor	Phase	Study Completion Date	Number of CALS Sites
<u>Lithium Chloride</u>	Multiple	Investigator Initiated	2/3	2011	15
<u>Ceftriaxone</u>	Excitotoxicity	Investigator Initiated	3	2011	8
<u>Dexpramipexole</u>	Mitochondria	Biogen Idec	3	2012	6
<u>Tirasemtiv</u>	Muscle	Cytokinetics	2	2014	12
<u>Ozanezumab</u>	Axon/ Neuromuscular Junction	GlaxoSmithKline	2	2017	5
<u>Tirasemtiv</u>	Muscle	Cytokinetics	3	2017	10
<u>NP001</u>	Inflammation	Neuraltus Pharmaceuticals, Inc.	2	2017	1
<u>Acthar Gel</u>	Inflammation	Mallinckrodt	2/3	2019	5
<u>Reldesemtiv</u>	Muscle	Cytokinetics	2	2019	9
<u>GDC-0134</u>	Axon Degeneration	Genentech, Inc.	1	2020	1
<u>Levosimendan</u>	Muscle	Orion	3	2020	9
<u>Ravulizumab</u>	Inflammation	Alexion	3	2021	7
<u>Tofersen (BIIB067)</u>	SOD1 Antisense Oligonucleotide (ASO)	Biogen/Ionis	1/2/3	2021	4
<u>Pimozide</u>	Neuromuscular Junction	Investigator Initiated	2	2021	9
<u>Tegoprunart (AT-1501)</u>	Inflammation	Eledon Pharmaceuticals	2	2022	1
<u>BIIB078</u>	C9ORF72 Antisense Oligonucleotide (ASO)	Biogen/Ionis	1	2022	4

<u>Withania Somnifera</u>	Inflammation	Investigator Initiated	2	2022	1
<u>WVE-004</u>	C9ORF72 Antisense Oligonucleotide (ASO)	Wave Therapeutics	1/2	2023	2
<u>Enoxacin</u>	miRNA	Investigator Initiated	1/2	2023	1
<u>MR-Guided FUS</u>	Blood Brain Barrier	Investigator Initiated	1	2022	1
<u>ABBV-CLS-7262</u>	EIF2b Activation	Calico Life Sciences LLC	1	2023	7
<u>AP-101</u>	SOD1 Antibody	AL-S Pharma	2	2023	4
<u>ANX005</u>	C1q inhibitor	Annexon, Inc.	2	2023	5
<u>Oral Edaravone</u>	Antioxidant	Mitsubishi Tanabe Pharma Development America, Inc.	3	2023	10
<u>ION363</u>	FUS Antisense Oligonucleotide (ASO)	Ionis	3	2024	1
<u>Ibudilast</u>	Inflammation	MediciNova	3	2024	6
<u>Reldesemtiv</u>	Muscle	Cytokinetics	3	2024	11
<u>SAR443820</u>	RIPK1 Inhibitor	Sanofi	2	2025	2 (so far)
<u>BIIB105</u>	Ataxin 2 Antisense Oligonucleotide (ASO)	Biogen/Ionis	1	2026	1
<u>Tofersen (Presymptomatic)</u>	SOD1 Antisense Oligonucleotide (ASO)	Biogen/Ionis	3	2027	2